| Anti-TNF user | Anti-TNF non-user | Increment (user vs non-user) | 95% CIa |
---|---|---|---|---|
Canada | ||||
 Costs | 15,741 | 1703 | 14,038 | (12,179, 15,991) |
 QALYs | 0.626 | 0.609 | 0.017 | (−0.008, 0.042) |
 ICER |  |  | 818,186 | (330,082, Dominated) |
France | ||||
 Costs | 15,773 | 1763 | 14,010 | (12,423, 15,694) |
 QALYs | 0.620 | 0.607 | 0.013 | (−0.011, 0.036) |
 ICER |  |  | 1,105,859 | (375,227, Dominated) |
UK | ||||
 Costs | 16,952 | 756 | 16,195 | (13,327, 19,181) |
 QALYs | 0.627 | 0.606 | 0.021 | (−0.015, 0.059) |
 ICER |  |  | 766,217 | (264,164, Dominated) |
Germany | ||||
 Costs | 15,617 | 1874 | 13,743 | (11,848, 15,759) |
 QALYs | 0.642 | 0.617 | 0.025 | (0.001, 0.050) |
 ICER |  |  | 545,808 | (272,286, 18,727,278) |
Hong Kong | ||||
 Costs | 15,764 | 722 | 15,042 | (11,825, 18,898) |
 QALYs | 0.619 | 0.586 | 0.033 | (−0.011, 0.076) |
 ICER |  |  | 456,850 | (189,636, Dominated) |